Rezolute to Participate in Upcoming Investor Conferences
Rezolute (Nasdaq: RZLT) announced management will participate in three investor conferences in late 2025: the Maxim Growth Summit on October 22-23, 2025, the Guggenheim 2nd Annual Healthcare Innovation Conference on November 10-12, 2025, and the Jefferies London Healthcare Conference on November 17-20, 2025.
Management expects to hold one-on-one investor meetings during the events. Investors who want to schedule meetings are instructed to contact their Maxim, Guggenheim, or Jefferies representative.
Rezolute (Nasdaq: RZLT) ha annunciato che il management parteciperà a tre conferenze per investitori nel tardo 2025: il Maxim Growth Summit il 22-23 ottobre 2025, la 2ª Conferenza annuale sull'Innovazione nella Sanità di Guggenheim dal 10 al 12 novembre 2025, e la Jefferies London Healthcare Conference dal 17 al 20 novembre 2025.
Il management prevede di tenere incontri individuali con gli investitori durante gli eventi. Gli investitori interessati a fissare incontri sono invitati a contattare il proprio rappresentante Maxim, Guggenheim o Jefferies.
Rezolute (Nasdaq: RZLT) anunció que la dirección participará en tres conferencias para inversionistas a finales de 2025: la Maxim Growth Summit los 22-23 de octubre de 2025, la Conferencia de Innovación en la Salud 2ª anual de Guggenheim del 10 al 12 de noviembre de 2025, y la Conferencia de Salud de Londres de Jefferies del 17 al 20 de noviembre de 2025.
La dirección espera mantener reuniones cara a cara con inversionistas durante los eventos. Los inversionistas que deseen programar reuniones deben contactar a su representante de Maxim, Guggenheim o Jefferies.
Rezolute (나스닥: RZLT)는 경영진이 2025년 말 세 차례의 투자자 컨퍼런스에 참여할 것이라고 발표했습니다: Maxim Growth Summit가 2025년 10월 22-23일, Guggenheim 제2차 연례 헬스케어 혁신 컨퍼런스가 2025년 11월 10-12일, 그리고 Jefferies 런던 헬스케어 컨퍼런스가 2025년 11월 17-20일에 열립니다.
경영진은 행사 중 일대일 투자자 면담을 개최할 예정입니다. 면담 일정을 원하시는 투자자분들은 Maxim, Guggenheim, 또는 Jefferies 담당자에게 연락하시기 바랍니다.
Rezolute (Nasdaq: RZLT) a annoncé que la direction participera à trois conférences pour investisseurs à la fin de 2025 : le Maxim Growth Summit du 22 au 23 octobre 2025, la 2e Conférence annuelle sur l'Innovation en Santé de Guggenheim du 10 au 12 novembre 2025, et la Jefferies London Healthcare Conference du 17 au 20 novembre 2025.
La direction prévoit d'organiser des réunions individuelles avec les investisseurs lors des événements. Les investisseurs qui souhaitent programmer des réunions doivent contacter leur représentant Maxim, Guggenheim ou Jefferies.
Rezolute (Nasdaq: RZLT) gab bekannt, dass die Geschäftsführung an drei Investorenkonferenzen Ende 2025 teilnehmen wird: dem Maxim Growth Summit am 22.-23. Oktober 2025, der Guggenheim 2nd Annual Healthcare Innovation Conference vom 10.-12. November 2025 und der Jefferies London Healthcare Conference vom 17.-20. November 2025.
Das Management erwartet während der Veranstaltungen Einzelgespräche mit Investoren zu führen. Investoren, die Meetings vereinbaren möchten, werden gebeten, den Maxim-, Guggenheim- oder Jefferies-Vertreter zu kontaktieren.
ريزلوت (ناسداك: RZLT) أعلنت الإدارة أنها ستشارك في ثلاث مؤتمرات للمستثمرين في أواخر عام 2025: Maxim Growth Summit في 22-23 أكتوبر 2025، وGuggenheim المؤتمر السنوي الثاني للابتكار في الرعاية الصحية في 10-12 نوفمبر 2025، وJefferies London Healthcare Conference في 17-20 نوفمبر 2025.
تتوقع الإدارة عقد لقاءات فردية مع المستثمرين خلال الفعاليات. المستثمرون الذين يرغبون في جدولة لقاءات يُطلب منهم الاتصال بمندوبهم لدى Maxim أو Guggenheim أو Jefferies.
Rezolute（纳斯达克：RZLT）宣布管理层将参加三场投资者会议，时间为2025年末：Maxim Growth Summit，于2025年10月22-23日举行；Guggenheim 第2届年度医疗保健创新会议，于2025年11月10-12日举行；以及Jefferies 伦敦医疗保健大会，于2025年11月17-20日举行。
管理层预计在活动期间进行一对一的投资者会谈。希望安排会谈的投资者请联系他们的Maxim、Guggenheim或Jefferies代表。
- None.
- None.
REDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:
Event: Maxim Growth Summit
Date: October 22-23, 2025
Event: Guggenheim 2nd Annual Healthcare Innovation Conference
Date: November 10-12, 2025
Event: Jefferies London Healthcare Conference
Date: November 17-20, 2025
Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their Maxim, Guggenheim, and Jefferies representatives.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown meaningful benefit in clinical trials and real-world use for the treatment of both congenital and tumor HI. For more information, visit www.rezolutebio.com.
Rezolute Contacts:
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
Carrie McKim
cmckim@rezolutebio.com
336-608-9706
FAQ
Which investor conferences will Rezolute (RZLT) attend in Oct–Nov 2025?
How can investors schedule a meeting with Rezolute management at the Maxim Growth Summit on Oct 22-23, 2025?
How do I arrange a one-on-one meeting with Rezolute management at the Guggenheim conference on Nov 10-12, 2025?
Who should investors contact to meet Rezolute management at the Jefferies London Healthcare Conference on Nov 17-20, 2025?
Will Rezolute (RZLT) hold one-on-one investor meetings during the listed conferences?
What is Rezolute's Nasdaq ticker and focus mentioned in the announcement dated Oct 15, 2025?
